Source: National Cancer Institute (NCI), Surveillance, Epidemiology, and End Results (SEER)
A high-sensitivity test for a high-risk population
This revolutionary new, investigational test is powered by a patented exosome-isolation technology that yields high sensitivity results from a simple blood draw. The test is designed to be used with patients and their family members who have been identified as having elevated risk for pancreatic cancer. These high-risk factors include genetic mutations or family history, the presence of lesions in the pancreas, or adults over the age of 50 with new onset diabetes. In this study, you will be asked to provide information and blood samples. You will not receive any information from the investigational test.
Biological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. The company’s proprietary ExoVerita™ platform simplifies isolation of extracellular vesicles, enabling multiomic applications. For more information, visit www.biologicaldynamics.com.